Romy Aarnoutse
Overview
Explore the profile of Romy Aarnoutse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillege L, Barnett D, Ziemons J, Aarnoutse R, de Vos-Geelen J, van Geel R, et al.
Sci Rep
. 2025 Mar;
15(1):7874.
PMID: 40050324
Tamoxifen is essential in treating estrogen receptor-positive (ER+) breast cancer, primarily through its active metabolite, endoxifen. Emerging research suggests potential interactions between tamoxifen and gut microbiota. This study investigates the...
2.
Hillege L, Trepka K, Ziemons J, Aarnoutse R, Guthrie B, de Vos-Geelen J, et al.
medRxiv
. 2024 Nov;
PMID: 39484258
Purpose: Unpredictable chemotherapy side effects are a major barrier to successful treatment. Cell culture and mouse experiments indicate that the gut microbiota is influenced by and influences anti-cancer drugs. However,...
3.
Ziemons J, Hillege L, Aarnoutse R, de Vos-Geelen J, Valkenburg-van Iersel L, Mastenbroek J, et al.
BMC Microbiol
. 2024 Jun;
24(1):222.
PMID: 38918717
Background: 5-Fluorouracil (5-FU) is used as an antineoplastic agent in distinct cancer types. Increasing evidence suggests that the gut microbiota might modulate 5-FU efficacy and toxicity, potentially affecting the patient's...
4.
Ziemons J, Aarnoutse R, Heuft A, Hillege L, Waelen J, de Vos-Geelen J, et al.
Clin Exp Med
. 2023 Apr;
23(7):3919-3933.
PMID: 37027066
Background: Gut bacteria-derived short-chain fatty acids (SCFA) and branched-chain fatty acids (BCFA) are considered to have beneficial metabolic, anti-inflammatory as well as anti-carcinogenic effects. Previous preclinical studies indicated bidirectional interactions...
5.
Aarnoutse R, Ziemons J, Hillege L, de Vos-Geelen J, de Boer M, Bisschop S, et al.
NPJ Breast Cancer
. 2022 Jul;
8(1):89.
PMID: 35906259
This clinical study explored the associations between the intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen receptor positive postmenopausal breast cancer patients were...
6.
Aarnoutse R, Hillege L, Ziemons J, de Vos-Geelen J, de Boer M, Aerts E, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944820
Background: Previous preclinical and clinical research has investigated the role of intestinal microbiota in carcinogenesis. Growing evidence exists that intestinal microbiota can influence breast cancer carcinogenesis. However, the role of...
7.
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine
Aarnoutse R, Ziemons J, de Vos-Geelen J, Valkenburg-van Iersel L, Wildeboer A, Vievermans A, et al.
Clin Colorectal Cancer
. 2021 Nov;
21(2):e87-e97.
PMID: 34801414
Background: Previous pre-clinical research has indicated that the intestinal microbiota can potentiate anti-tumour efficacy of capecitabine and that capecitabine treatment impacts intestinal microbiota composition and diversity. Using a longitudinal design,...
8.
Ubachs J, Ziemons J, Soons Z, Aarnoutse R, van Dijk D, Penders J, et al.
J Cachexia Sarcopenia Muscle
. 2021 Oct;
12(6):2007-2021.
PMID: 34609073
Background: Cancer cachexia is characterized by a negative energy balance, muscle and adipose tissue wasting, insulin resistance, and systemic inflammation. Because of its strong negative impact on prognosis and its...
9.
Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, et al.
Cell Death Differ
. 2021 May;
28(9):2778-2796.
PMID: 33963313
The prognosis of early breast cancer (BC) relies on cell autonomous and immune parameters. The impact of the intestinal microbiome on clinical outcome has not yet been evaluated. Shotgun metagenomics...
10.
Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response
Dieleman S, Aarnoutse R, Ziemons J, Kooreman L, Boleij A, Smidt M
Am J Pathol
. 2021 Mar;
191(6):968-982.
PMID: 33713687
Breast cancer tissue contains its own unique microbiota. Emerging preclinical data indicates that breast microbiota dysbiosis contributes to breast cancer initiation and progression. Furthermore, the breast microbiota may be a...